Potentiation of the 5-aminolevulinic acid-based photodynamic therapy with cyclophosphamide

We have investigated the efficacy of the Photodynamic Therapy (PDT) from 5-aminolevulinic acid (ALA) in combination with an antineoplastic agent using an in vitro-in vivo model developed in our laboratory. The alkylant cyclophosphamide (CY) was chosen because there is evidence of the porphyrinogenic...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Casas, A.
Otros Autores: Fukuda, H., Batlle, A.M.D.C
Formato: Capítulo de libro
Lenguaje:Inglés
Publicado: 1997
Acceso en línea:Registro en Scopus
Handle
Registro en la Biblioteca Digital
Aporte de:Registro referencial: Solicitar el recurso aquí
LEADER 08512caa a22010217a 4500
001 PAPER-3065
003 AR-BaUEN
005 20230518203232.0
008 190411s1997 xx ||||fo|||| 00| 0 eng|d
024 7 |2 scopus  |a 2-s2.0-0343341094 
024 7 |2 cas  |a Aminolevulinic Acid, 106-60-5; Antineoplastic Agents, Alkylating; Cyclophosphamide, 50-18-0; Photosensitizing Agents; Porphyrins 
040 |a Scopus  |b spa  |c AR-BaUEN  |d AR-BaUEN 
030 |a CABCD 
100 1 |a Casas, A. 
245 1 0 |a Potentiation of the 5-aminolevulinic acid-based photodynamic therapy with cyclophosphamide 
260 |c 1997 
270 1 0 |m Batlle, A.M.D.C.Viamonte 1881 10A, 1056 Buenos Aires, Argentina 
506 |2 openaire  |e Política editorial 
504 |a Cairnduff, F., Stringer, M.R., Hudson, E.J., Ash, D.V., Brown, S.B., Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer (1994) Br. J. Cancer, 69, pp. 605-608 
504 |a Cowled, P.A., Mackenzie, L., Forbes, I.J., Pharmacological modulation of photodynamic therapy with hematoporphyrin derivative and light (1987) Cancer Res., 47, pp. 971-974 
504 |a Dougherty, T.J., Potter, W.R., Belliner, D., Photodynamic therapy for for the treatment of cancer, current status and advances (1990) Photodynamic Therapy of Neoplastic Disease, pp. 1-19. , D. Kessel (Ed.) CRC Press, Boca Raton, FL 
504 |a Falk, J., Porphyrins and metalloporphyrins (1964) Biochim. Biophys. Acta Library, 2. , Elsevier Publishing Company, Amsterdam. London, New York 
504 |a Fukuda, H., Paredes, S., Del C. Batlle, A.M., Tumor-localizing properties of porphyrins. In vitro studies using the porphyrin precursor, aminolevulinic acid, in free and liposome encapsulated forms (1989) Drug Des. Deliv., 5, pp. 133-139 
504 |a Fukuda, H., Paredes, S., Casas, A., Chueke, F., Del C. Batlle, A.M., Potential of liposome-entrapped aminolevulinic acid in cancer therapy. Effect of prior injection of empty liposomes and different routes of administration (1992) Cancer J., 5, pp. 295-299 
504 |a Fukuda, H., Paredes, S., Del C. Batlle, A.M., Tumor-localizing properties of porphyrins. In vivo studies using free and liposome encapsulated aminolevulinic acid (1992) Comp. Biochem. Physiol., 2, pp. 433-436 
504 |a Fukuda, H., Casas, A., Chueke, F., Paredes, S., Batlle, A., Photodynamic action of endogenously synthesized porphyrins from aminolevulinic acid, using a new model for assaying the effectiveness of tumoral cell killing (1993) Int. J. Biochem., 25, pp. 1395-1398 
504 |a Jin, M.L., Yang, B.Q., Zhang, W., Ren, P., Combined treatment of photodynamic therapy and chemotherapy for advanced cardiac cancers (1992) J. Photochem, Photobiol. B. Biol., 12, pp. 101-106 
504 |a Kelly, J.F., Snell, M.E., Hematoporphyrin derivative: A possible aid in the diagnosis and therapy of carcinoma of the bladder (1976) J. Urol, 115, pp. 150-157 
504 |a Lipson, R.L., Baldes, E.J., Olsen, A.M., The use of a derivative of hematoporphyrin in tumor detection (1965) J. Natl. Cancer Inst., 26, pp. 1-11 
504 |a Ma, L.W., Moan, J., Steen, H.B., Iani, V., Anti-tumour activity of photodynamic therapy in combination with mitomycin C in nude mice with human colon adenocarcinoma (1995) Br. J. Cancer, 71, pp. 950-956 
504 |a Malik, Z., Lugaci, H., Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins (1987) Br. J. Cancer, 56, pp. 589-595 
504 |a Nahabedian, M.Y., Cohen, R.A., Contino, M.F., Terem, T.M., Wright, W.H., Berns, M.W., Wile, A.G., Combination cytotoxic chemotherapy with cisplatin or doxorubicin and photodynamic therapy in murine tumors (1988) J. Natl. Cancer Inst., 80, pp. 739-743 
504 |a Palma-Carlos, A.G., Palma-Carlos, M.L., Lourenco, M.G., Martins-Silva, J.A., Effect of alkylating agents on haem metabolism (1971) S. Afr. J. Lab, Clin. Med., 25, pp. 81-84 
504 |a Regula, J., Ravi, B., Bedwell, J., MacRobert, A.J., Bown, S.G., Photodynamic therapy using 5-aminolaevulinic acid for experimental pancreatic cancer - Prolonged animal survival (1994) Br. J. Cancer, 70, pp. 248-254 
504 |a Rizzardini, M., Ferraroli, D., Dal Fiume, D., Cantoni, L., Cyclophosphamide-impaired regulation of hepatic heme metabolism (1984) Experientia, 40, pp. 1390-1392 
504 |a Vázquez, E., Afonso, S., Buzaleh, A.M., Navone, N., Polo, C., Schoua, E., Batlle, A., The effect of griseofulvin on the heme pathway Studies on tissue explant cultures (1987) Toxicology, 46, pp. 73-82 
504 |a Wainstok, R., San Martin De Viale, L., Effect of some antineoplasics on metabolic heme pathway (1988) Int. J. Biochem., 20, pp. 1015-1020 
520 3 |a We have investigated the efficacy of the Photodynamic Therapy (PDT) from 5-aminolevulinic acid (ALA) in combination with an antineoplastic agent using an in vitro-in vivo model developed in our laboratory. The alkylant cyclophosphamide (CY) was chosen because there is evidence of the porphyrinogenic properties of this drug. Male BALB/c mice bearing a transplantable mammary adenoarcinoma were given two doses of 35 mg de CY/kg wt. i.p. and 9 mg/kg wt intratumorally. At 16, 22 and 40 hrs after the last injection of CY the animals were sacrificed and explants of 2 mg of tumor were incubated 2 hrs in a medium containing 0.6 mM ALA; and then irradiated with a He-Ne laser. Innocula of 1 mm3 of irradiated and nonirradiated tissue were then injected subcutaneously under the right and left flanks of a normal mouse, respectively. The efficacy of the treatment was determined following the growth of the tumor from day 10 after tumor implantation. Under the present conditions a 30% increased efficacy was observed in the case of the explants treated with CY 40 hrs after the last i.p. injection. Porphyrins in the liver and tumor and other tissues of the injected mice were also determined; except for a slight increase in tumor and liver, 40 and 22 hrs after CY i.p. injection respectively, no other changes were observed in any tissue, as compared with not CY treated mice. These results indicate that future treatment, combining the tumor localizing properties of endogenously formed porphyrins from ALA and antineoplasic drugs such as cyclophosphamide, should be encouraged.  |l eng 
593 |a Viamonte 1881 10A, 1056 Buenos Aires, Argentina 
593 |a Ctro. Invest. Sobre Porfirinas y P., Ciudad Universitaria, Pabellón II, 1428, Buenos Aires, Argentina 
690 1 0 |a 5-AMINOLEVULINIC ACID 
690 1 0 |a CYCLOPHOSPHAMIDE 
690 1 0 |a PHOTODYNAMIC THERAPY 
690 1 0 |a ALKYLATING AGENT 
690 1 0 |a AMINOLEVULINIC ACID 
690 1 0 |a CYCLOPHOSPHAMIDE 
690 1 0 |a PHOTOSENSITIZING AGENT 
690 1 0 |a PORPHYRIN 
690 1 0 |a ADENOCARCINOMA 
690 1 0 |a ANIMAL 
690 1 0 |a ARTICLE 
690 1 0 |a BAGG ALBINO MOUSE 
690 1 0 |a BIOSYNTHESIS 
690 1 0 |a CHEMISTRY 
690 1 0 |a EXPERIMENTAL NEOPLASM 
690 1 0 |a LIVER 
690 1 0 |a MALE 
690 1 0 |a METABOLISM 
690 1 0 |a MOUSE 
690 1 0 |a MULTIMODALITY CANCER THERAPY 
690 1 0 |a PHOTOCHEMOTHERAPY 
690 1 0 |a TIME 
690 1 0 |a TISSUE DISTRIBUTION 
690 1 0 |a ADENOCARCINOMA 
690 1 0 |a AMINOLEVULINIC ACID 
690 1 0 |a ANIMALS 
690 1 0 |a ANTINEOPLASTIC AGENTS, ALKYLATING 
690 1 0 |a COMBINED MODALITY THERAPY 
690 1 0 |a CYCLOPHOSPHAMIDE 
690 1 0 |a LIVER 
690 1 0 |a MALE 
690 1 0 |a MAMMARY NEOPLASMS, EXPERIMENTAL 
690 1 0 |a MICE 
690 1 0 |a MICE, INBRED BALB C 
690 1 0 |a PHOTOCHEMOTHERAPY 
690 1 0 |a PHOTOSENSITIZING AGENTS 
690 1 0 |a PORPHYRINS 
690 1 0 |a TIME FACTORS 
690 1 0 |a TISSUE DISTRIBUTION 
700 1 |a Fukuda, H. 
700 1 |a Batlle, A.M.D.C. 
773 0 |d 1997  |g v. 16  |h pp. 183-196  |k n. 1  |p Cancer Biochem. Biophys.  |x 03057232  |t Cancer Biochemistry Biophysics 
856 4 1 |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-0343341094&partnerID=40&md5=444698e112bbc2857649296fb918293f  |y Registro en Scopus 
856 4 0 |u https://hdl.handle.net/20.500.12110/paper_03057232_v16_n1_p183_Casas  |y Handle 
856 4 0 |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_03057232_v16_n1_p183_Casas  |y Registro en la Biblioteca Digital 
961 |a paper_03057232_v16_n1_p183_Casas  |b paper  |c PE 
962 |a info:eu-repo/semantics/article  |a info:ar-repo/semantics/artículo  |b info:eu-repo/semantics/publishedVersion 
999 |c 64018